Before I get started I wanted to share that my father, Ted Killingsworth, has passed-away. He was surrounded by nearly a dozen family members. They reassure me he was comfortable and quietly slipped-away. I will post an obit sometime next week. I will miss you, Dad! Thursday evening I participated in a Q & A
I had it all planned-out: arrive at the airport early so I could work and complete and post today's news. But 12,000 Northwestern Mutual Life conventioneers had other plans! It took me an hour to check my bag and make it part way through an endless security line, only to realize I was about to
The myeloma world doesn't stop turning just because I"m out of town visiting my father. Let's catch-up on a few important odds 'n ends today. First, I received an email from a reader, questioning the value of the Mayo Clinic retrospective study that Danny Parker and I reported on yesterday. The issue: the study or
Awesome Patient Power video features Dr. Shaji Kumar discussing how new understanding of myeloma pathology and therapy is moving the multiple myeloma treatment field toward personalization to improve outcomes. There are now a large variety of treatment options for patients with multiple myeloma. Patients are also living longer and better with this disease, making it
Last night I was one of four multiple myeloma patient panel members that participated on Cure Talk's Myeloma Cure Panel broadcast. The group included fellow Floridian and host, Gary Petersen, Jack Aiello from Northern California and Cynthia Chmielewski from New Jersey. We had an opportunity to question myeloma experts, Dr. Shaji Kumar, from the Mayo
Mayo Clinic’s Dr. Shaji Kumar Continues Investigation Into The Biggest Single Question Facing Multple Myeloma Patients Today: Should You Transplant Now Or Later?
I saved the last edition of the International Myeloma Foundation's (IMF) Myeloma Today on my "get to as soon as possible" pile near my computer. The full color newsletter, done very professionally in color, on thick, glossy stock, was folded open to an article about Dr. Shaji Kumar's ongoing study comparing continued initial therapy and
The three novel chemotherapy agents (Revlimid, Velcade, Thalomid) now commonly used to treat multiple myeloma have been so successful it has created an unforeseen problem. According to Dr. Shaji Kumar with Mayo Clinic, improved outcomes for the majority of myeloma patients using these drugs makes it more difficult to bring other, new drugs to market.